Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Nov
16
Today In Oncology
Pancreatic Cancer Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
SABR May Be Comparable to Surgery for Early-Stage NSCLC
MD Anderson Launches 2.5 Billion Philanthropic Campaign
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo